ClindaReach

ClindaReach is a topical antibiotic formulation containing clindamycin phosphate (1%) indicated for the treatment of acne vulgaris. As a member of the lincosamide class, it acts by binding to the 50S ribosomal subunit of susceptible bacteria, effectively inhibiting protein synthesis. This action reduces the population of *Propionibacterium acnes* on the skin and decreases the concentration of surface fatty acids. Originally manufactured by Sirius, a subsidiary of DUSA Pharmaceuticals, ClindaReach is typically supplied as medicated pledgets for easy topical application. It was the subject of an FDA alert in 2010 regarding manufacturing standards.

Brand names

ClindaReach

Other names

clindamycin phosphate